In the article “Companies Desperately Seek Antidepressant
Breakthrough” in the June 2 issue, the investigational antidepressant
medication desvenlafaxine was incorrectly said to be under development by
GlaxoSmithKline (GSk). The drug is actually under development by Wyeth, which
also developed and markets venlafaxine (Effexor), the parent compound of
desvenlafaxine. A chart accompanying the article correctly listed Wyeth as the
developer. ▪